Christopher P. Cannon MDEducation Director, Cardiovascular Innovation, Cardiovascular Division, Brigham and Women’s Hospital; Professor of Medicine, Harvard Medical School; Remote faculty, Clinician-Scientist, CPC Clinical Research Institute, Boston, Massachusetts
Dr. Cannon is a Professor of Medicine at Harvard Medical School, and senior physician in the Preventive Cardiology section of the Cardiovascular Division at Brigham and Women’s Hospital. He serves as Education Director in the Cardiovascular Innovation group and has recently joined the remote faculty as a Clinician Scientist at the CPC Clinical Research Institute. Previously, he worked for 25 years as an investigator in the TIMI Study Group, then for 9 years the Harvard Clinical Research Institute/Baim Institute.
He earned his MD from Columbia University College of Physicians and Surgeons in New York and did internal medicine residency at Columbia Presbyterian Medical Center, and cardiovascular fellowship at Brigham and Women’s Hospital.
Dr. Cannon has published over 1000 original articles, reviews, or book chapters in the field of acute coronary syndromes and prevention and has authored or edited 20 books. He has received numerous awards, including leadership awards from the American College of Cardiology, American Heart Association and National Lipid Association.
He has been principal investigator of more than 20 multicenter clinical trials, including TACTICS-TIMI 18, PROVE IT, IMPROVE IT, RE-DUAL PCI and VERTIS CV trials. He is currently working on clinical trials, registries, and quality improvement projects in the fields of acute coronary syndromes, atrial fibrillation, diabetes, lipids and prevention. In his role at Cardiovascular Innovation, he is helping implement quality improvement programs using telemedicine for lipids, hypertension, and diabetes, and at CPC Clinical Research he helps lead pragmatic clinical trials.
Dr. Cannon reports in calendar years 2021 to 2023:
- Research Grants from: Amgen, Better Therapeutics, Boehringer-Ingelheim (BI), Daiichi Sankyo, Merck, Novo Nordisk, Pfizer
- Consulting fees from Amryt/Chiesi, Alnylam, Amarin, Amgen, Applied Therapeutics, Ascendia, Biogen, BI, BMS, CSL Behring, Eli Lilly, Janssen, Lexicon, Merck, Milestone, Pfizer, Rhoshan, Sanofi
Dr. Cannon serves on Data and Safety Monitoring Boards for the Applied Therapeutics, Areteia and Novo Nordisk.
Recent Contributions to PracticeUpdate:
- LDL-C Level Reduction With Lipid-Lowering Therapy for Primary Prevention of Major Vascular Events Among Older Individuals
- Long-Term Efficacy and Safety of Moderate-Intensity Statin With Ezetimibe Combination Therapy vs High-Intensity Statin Monotherapy in Patients With ASCVD
- Prophylactic Rivaroxaban Therapy for LV Thrombus After Anterior STEMI
- Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function
- Effect of Empagliflozin on the Clinical Stability in HFrEF
- MY APPROACH to Patients Taking Aspirin for Primary Prevention
- PCSK9 Inhibitor Price Reduction Essential for Cost-Effectiveness
- Evacetrapib Does Not Reduce Cardiovascular Risk in High-Risk Vascular Disease
- Antiplatelet Therapy for Patients With Stable CAD and AF on Oral Anticoagulants
- Coxibs and Diclofenac High-Risk NSAIDs for Vascular Events While Ibuprofen on Shaky Ground and Naproxen Appears Safe